 Connection
Marc Bonaca to Receptor, PAR-1
This is a "connection" page, showing publications Marc Bonaca has written about Receptor, PAR-1.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.383 |
|
|
|
-
Bonaca MP, Creager MA, Olin J, Scirica BM, Gilchrist IC, Murphy SA, Goodrich EL, Braunwald E, Morrow DA. Peripheral Revascularization in Patients With Peripheral Artery Disease With Vorapaxar: Insights From the TRA 2°P-TIMI 50 Trial. JACC Cardiovasc Interv. 2016 10 24; 9(20):2157-2164.
Score: 0.132
-
Bonaca MP, Scirica BM, Creager MA, Olin J, Bounameaux H, Dellborg M, Lamp JM, Murphy SA, Braunwald E, Morrow DA. Vorapaxar in patients with peripheral artery disease: results from TRA2{degrees}P-TIMI 50. Circulation. 2013 Apr 09; 127(14):1522-9, 1529e1-6.
Score: 0.103
-
Bonaca MP, Morrow DA. SCH 530348: a novel oral thrombin receptor antagonist. Future Cardiol. 2009 Sep; 5(5):435-42.
Score: 0.080
-
Correa S, Bonaca MP, Scirica BM, Murphy SA, Goodrich EL, Morrow DA, O'Donoghue ML. Efficacy and safety of more potent antiplatelet therapy with vorapaxar in patients with impaired renal function. J Thromb Thrombolysis. 2019 Apr; 47(3):353-360.
Score: 0.039
-
Magnani G, Bonaca MP, Braunwald E, Dalby AJ, Fox KA, Murphy SA, Nicolau JC, Oude Ophuis T, Scirica BM, Spinar J, Theroux P, Morrow DA. Efficacy and safety of vorapaxar as approved for clinical use in the United States. J Am Heart Assoc. 2015 Mar 19; 4(3):e001505.
Score: 0.029
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|